Public health & disease

From disease eradication efforts to advances in vaccination and maternal health, this archive tracks real progress in public health. Stories here focus on what’s working — policies, interventions, and research that are improving and extending lives around the world.

Cannabis being weighed, for article on legal cannabis dispensary, for article on Germany cannabis legalization

New York opens its first legal recreational cannabis dispensary

By / / Good News For Humankind

New York’s first legal recreational cannabis dispensary opened with a meaningful twist: the very first retail license went to Housing Works, a nonprofit that serves people with HIV, homeless New Yorkers, and the formerly incarcerated. Revenue from the shop will flow back into those social services, turning a newly legal market into direct support for communities hit hardest by the war on drugs. New York reserved its earliest licenses for nonprofits, people with past marijuana convictions and their families, women- and minority-owned businesses, and veterans, backed by a $200 million equity fund. It’s an ambitious bet that legalization can repair harm rather than just generate profit, and other states are paying close attention.

DNA, for article on artificial DNA cancer

In a world first, Japenese scientists use artificial DNA to kill cancer cells

By / / Good News For Humankind

Artificial DNA that turns cancer’s own biology against itself marks a genuine conceptual leap in oncology. Japanese researchers at the University of Tokyo engineered synthetic molecules that lie dormant until they detect a chemical cancer cells overproduce — then restructure themselves into a signal the immune system reads as a threat, destroying the tumor from within. Early tests spanned multiple cancer types, suggesting broad potential. This kind of precision — working with the body’s existing defenses rather than overwhelming them — is exactly the direction cancer medicine has been reaching toward, and this research moves that goal meaningfully closer.

3M mask, for article on PFAS phase-out

3M to end ‘forever chemicals’ output at cost of up to $2.3 bn

By / / Good News For Humankind

3M, one of the world’s largest makers of PFAS, will halt all production of these “forever chemicals” by the end of 2025, walking away from a business that brought in roughly $1.3 billion a year. The company expects to absorb up to $2.3 billion in pre-tax charges to exit — a sign it sees long-term liability as the bigger risk than lost revenue. The move follows mounting pressure from regulators, lawsuits, and a coalition of fund managers overseeing $8 trillion in assets who urged dozens of companies to phase PFAS out. Compounds linked to cancer, thyroid disruption, and developmental harm have turned up in drinking water and food supplies worldwide, and 3M’s deadline signals that the era of treating them as ordinary industrial inputs is drawing to a close.

Brain model, for article on glioblastoma vaccine

Vaccine prolongs life of patients with aggressive brain cancer in new trial

By / / Good News For Humankind

Glioblastoma patients now have the most promising new treatment in nearly three decades, after a personalised vaccine more than doubled five-year survival rates in a large international trial. The vaccine works by extracting proteins from a patient’s own tumour and combining them with their white blood cells, training the immune system to recognise and destroy the cancer — with benefits seen even among those traditionally considered hardest to treat. If regulators approve it, this could signal a new era of personalised immunotherapy for cancers that have long resisted every available option.